Comments
Granules India’s wholly-owned foreign subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Lisdexamfetamine Dimesylate Capsules.
The generic drug product is bioequivalent and therapeutically equivalent to the reference listed drug, Vyvanse Capsules of Takeda Pharmaceuticals U.S.A., Inc. Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and paediatric patients aged six years and older, as well as for Moderate to Severe Binge Eating Disorder (BED) in adults.
The approval follows the company’s recent December 2024 USFDA approval for Lisdexamfetamine Dimesylate Chewable Tablets, further expanding Granules’ comprehensive portfolio in the ADHD therapeutic segment and demonstrating the company’s commitment to providing multiple treatment options for patients.
Latest approval
With this latest approval, Granules India Limited now holds a total of 69 ANDA approvals, with 38 secured under the name of Granules India Limited (GIL) and 31 under Granules Pharmaceuticals, Inc. (GPI).
“With this latest approval, we are reinforcing our presence in the ADHD treatment space and strengthening our portfolio of complex generics,’‘ Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India said in a release.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.